Security
GNPX · Genprex, Inc.
GNPXNASDAQCommon stockCurrentCIK 1595248Updated Sep 24, 2026
GNPX price & chart
Loading TradingView…
NASDAQ:GNPX on TradingView ↗About the company
We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, our technology is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.
In the news
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules News provided by Genprex, Inc. Oct 23, 2025, 08:12 ET Share this article Share to X Share this article Share to X $2.7 million upfront with up to an additional $5.4 million of potential aggrega ↗
Recent filings
Other Events
Items 8.01, 9.01
10-Q filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01, 9.01
Other Events
Items 8.01, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events
Items 3.01, 8.01, 9.01
Show 5 more recent filings
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure · Other Events
Items 3.03, 5.03, 7.01, 8.01, 9.01
S-8 filing
Other Events
Items 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events
Items 3.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 10,159,011Source | 4,124,325Source | 10,670,592Source | 25,085,027Source |
| Property, Plant and Equipment, NetUSD | 0Source | 0Source | 7,859Source | 23,032Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 0Source | 773,478Source | 702,095Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,830,855Source | 1,601,660Source | 6,737,629Source | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 0Source | 34,852Source |
| Assets, CurrentUSD | 8,356,783Source | 2,077,467Source | 7,531,767Source | 21,473,145Source |
| Prepaid Expense and Other Assets, CurrentUSD | 525,928Source | 475,807Source | 794,138Source | 484,224Source |
| Other Assets, NoncurrentUSD | 1,802,228Source | 2,046,858Source | 3,130,966Source | 3,588,850Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,197,135Source | — | — | — |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 3,291Source | 10,861Source | 1,486Source | 48,106Source |
| Additional Paid in CapitalUSD | 178,986,981Source | 156,408,737Source | 141,103,178Source | 125,054,453Source |
| Retained Earnings (Accumulated Deficit)USD | -171,028,396Source | -154,799,443Source | -133,688,280Source | -102,827,819Source |
| Stockholders' Equity Attributable to ParentUSD | 7,961,876Source | 1,620,155Source | 7,416,384Source | 22,274,740Source |
| Liabilities and EquityUSD | 10,159,011Source | 4,124,325Source | 10,670,592Source | 25,085,027Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,174,635Source | 2,504,170Source | 3,254,208Source | 2,810,287Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | 3,302,982Source | 5,408,728Source | 4,731,944Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | 0Source | -34,852Source | 34,852Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -15,311,209Source | -17,149,088Source | -24,738,603Source | -17,778,964Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | 1,166Source | -71,214Source | 97,731Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | 0Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 21,540,404Source | 12,011,953Source | 10,593,377Source | 6,426Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 6,229,195Source | -5,135,969Source | -14,216,440Source | -17,674,807Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 300,000Source | 3,300,000Source | — | — |
| Amortization of Intangible AssetsUSD | — | 773,478Source | — | — |
| DepreciationUSD | 0Source | 6,693Source | 15,004Source | 25,575Source |
| General and Administrative ExpenseUSD | 6,086,899Source | 10,632,028Source | 13,443,961Source | 12,295,070Source |
| Income Tax Expense (Benefit)USD | 0Source | 2,650Source | 0Source | — |
| Investment Income, InterestUSD | — | 63,574Source | 215,109Source | 90,098Source |
| Net Income (Loss) Attributable to ParentUSD | -16,228,953Source | -21,111,163Source | -30,860,461Source | -23,740,621Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -16,228,953Source | -21,388,282Source | — | — |
| Proceeds from Issuance of Common StockUSD | 21,540,404Source | 12,011,953Source | 10,593,377Source | 6,426Source |
| Realized Investment Gains (Losses)USD | -299Source | -570Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 0Source | 0Source | 0Source |
| Operating Income (Loss)USD | -15,515,619Source | -21,174,167Source | -31,075,570Source | -23,830,719Source |
| Income Tax Expense (Benefit)USD | 0Source | 2,650Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | -16,228,953Source | -21,111,163Source | -30,860,461Source | -23,740,621Source |
| Earnings Per Share, BasicUSD per share | -17.4Source | -5.34Source | -22.56Source | -0.5Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 932,730Source | 4,005,994Source | 1,367,747Source | 47,952,100Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | 773,478Source | — | — |
| Costs and ExpensesUSD | 15,515,619Source | 21,174,167Source | 31,075,570Source | 23,830,719Source |
| Current Income Tax Expense (Benefit)USD | 0Source | 2,650Source | 0Source | — |
| General and Administrative ExpenseUSD | 6,086,899Source | 10,632,028Source | 13,443,961Source | 12,295,070Source |
| Investment Income, InterestUSD | — | 63,574Source | 215,109Source | 90,098Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -16,228,953Source | -21,388,282Source | — | — |
| Realized Investment Gains (Losses)USD | -299Source | -570Source | — | — |
| Research and Development ExpenseUSD | 9,428,720Source | 10,535,446Source | 17,616,605Source | 11,510,074Source |